Efficacy of infliximab in extrapulmonary sarcoidosis: Results from a randomised trial

European Respiratory Journal

Volumn 31, Issue 6, 2008, Pages 1189-1196

  Judson, M A ^a,ak   Baughman, R P ^b   Costabel, U ^e,ag   Flavin, S ^d   Lo, K H ^d   Kavuru, M S ^c   Drent, M ^f   Culver, D A ^c   Davis, G S ^g   Fogarty, C M ^h   Hunninghake, G W ⁱ   Teirstein, A S ^j   Mandel, M ^k   McNally, D ^l   Tanoue, L ^m   Newman, L ⁿ   Wasfi, Y ⁿ   Patrick, H ^o   Rossman, M D ^p   Raghu, G ^q   Sharma, O ^r   Wilkes, D ^s   Yeager, H ^t   Donahue, J F ^u   Kaye, M ^v   Sweiss, N ^w   Vetter, N ^x   Thomeer, M ^y   Brutsche, M ^z   Nicod, L ^aa   Valeyre, D ^ab   Chanez, P ^ac   Albera, C ^ad   Grutters, J ^ae   Hoogsteden, H ^af   Muller Quernheim, J ^ah   Bonnet, R ^ai   Kanniess, F ^aj   more..

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d CENTOCOR INC   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF VERMONT   (United States)

^h University of Vermont Lung Center ^*  (United States)

ⁱ UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^j MOUNT SINAI MEDICAL CENTER   (United States)

^k Pulmonary Research Associates LLC   (United States)

^l UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^m YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^o DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^p HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^q UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^r UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^s INDIANA UNIVERSITY   (United States)

^t GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^u UNIVERSITY OF NORTH CAROLINA   (United States)

^v Minnesota Lung Center   (United States)

^w UNIVERSITY OF CHICAGO   (United States)

^x OTTO WAGNER HOSPITAL   (Austria)

^y UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^z UNIVERSITY HOSPITAL BASEL   (Switzerland)

^aa UNIVERSITY OF BERN   (Switzerland)

^ab AVICENNE HOSPITAL   (France)

^ac HÔPITAL ARNAUD DE VILLENEUVE   (France)

^ad SAN LUIGI GONZAGA HOSPITAL   (Italy)

^ae ST ANTONIUS HOSPITAL   (Netherlands)

^af ERASMUS MEDICAL CENTER   (Netherlands)

^ag RUHRLANDKLINIK   (Germany)

^ah UNIVERSITY OF FREIBURG   (Germany)

^ai ZENTRALKLINIK BAD BERKA   (Germany)

^aj KRANKENHAUS GROSSHANSDORF   (Germany)

^ak MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

more..

Author keywords

Extrathoracic; Infliximab; Sarcoidosis; Severity; Therapy

Indexed keywords

INFLIXIMAB; PLACEBO; PREDNISONE; ANTIINFLAMMATORY AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY;

ADULT; ANAPHYLAXIS; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HYPERSENSITIVITY REACTION; LUNG SARCOIDOSIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DRUG COMBINATION; HOSPITALIZATION; MIDDLE AGED; SARCOIDOSIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; SARCOIDOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 49649098822     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00051907     Document Type: Article

References (25)

1. Judson MA. An approach to the treatment of pulmonary sarcoidosis with corticosteroids: the six phases of treatment. Chest 1999; 115: 1158-1165.
2. Lynch JP 3rd, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18: 755-785.
3. Baughman RP, Lower EE. A clinical approach to the use of methotrexate for sarcoidosis. Thorax 1999; 54: 742-746.
4. Jones E, Callen JP. Hydroxychloroquine is effective therapy for control of cutaneous sarcoidal granulomas. J Am Acad Dermatol 1990; 23: 487-489.
5. Müller-Quernheim J, Kienast K, Held M, Pfeifer S, Costabel U. Treatment of chronic sarcoidosis with an azathioprine/prednisolone regimen. Eur Respir J 1999; 14: 1117-1122.
6. Lower EE, Broderick JP, Brott TG, Baughman RP. Diagnosis and management of neurological sarcoidosis. Arch Intern Med 1997; 157: 1864-1868.
7. Doty JD, Mazur JE, Judson MA. Treatment of corticosteroid-resistant neurosarcoidosis with a short-course cyclophosphamide regimen. Chest 2003; 124: 2023-2026.
8. Judson MA, Silvestri J, Hartung C, Byars T, Cox CE. The effect of thalidomide on corticosteroid-dependent pulmonary sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 51-57.
9. Zabel P, Entzian P, Dalhoff K, Schlaak M. Pentoxifylline in treatment of sarcoidosis. Am J Respir Crit Care Med 1997; 155: 1665-1669.
10. Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 70-74.
11. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005; 127: 1064-1071.
12. Heffernan MP, Anadkat MJ. Recalcitrant cutaneous sarcoidosis responding to infliximab. Arch Dermatol 2005; 141: 910-911.
13. Carter JD, Valeriano J, Vasey FB, Bognar B. Refractory neurosarcoidosis: a dramatic response to infliximab. Am J Med 2004; 15, 117: 277-279.
14. Hoitsma E, Faber CG, van Santen-Hoeufft M, De Vries J, Reulen JP, Drent M. Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23: 73-77.
15. Fehrenbach H, Zissel G, Goldmann T, et al. Alveolar macrophages are the main source for tumour necrosis factor-α in patients with sarcoidosis. Eur Respir J 2003; 21: 421-428.
16. Zissel G, Müller-Quernheim J. Sarcoidosis: historical perspective and immunopathogenesis (Part I). Respir Med 1998; 92: 126-139.
17. Ziegenhagen MW, Rothe ME, Zissel G, Müller-Quernheim J. Exaggerated TNFα release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 185-190.
18. Mañá J, Marcoval J, Graells J, Salazar A, Peyrí J, Pujol R. Cutaneous involvement in sarcoidosis. Relationship to systemic disease. Arch Dermatol 1997; 133: 882-888.
19. Sharma OP. Sarcoidosis of the upper respiratory tract. Selected cases emphasizing diagnostic and therapeutic difficulties. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19: 227-233.
20. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002; 301: 418-426.
21. Baughman RP, Drent M, Kavuru M, et al. Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement. Am J Respir Crit Care Med 2006; 174: 795-802.
22. Fletcher CM. Standardised questionnaire on respiratory symptoms: a statement prepared and approved by the MRC Committee on the Aetiology of Chronic Bronchitis (MRC breathlessness score). BMJ 1960; 2: 1665.
23. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systemic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006; 295: 2275-2285.
24. Judson MA, Baughman RP, Teirstein AS, Terrin ML, Yeager H Jr. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case-Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 75-86.
25. Wasfi YS, Rose CS, Murphy JR, et al. A new tool to assess sarcoidosis severity. Chest 2006; 129: 1234-1245.